Biosimilar monoclonal antibodies are defined as biological molecules derived from the living cells or the organisms. They have the complex, large proteins of biosimilar family used over by immune system to identify and neutralize the foreign bodies associated to bacteria, viruses, and others. These antibodies are largely administered over by the treatment of diseases associated to rheumatoid arthritis, Hodgkins lymphoma, chronic lymphocytic leukemia, and others. The Biosimilar Monoclonal Antibody market to witness the prominent growth owing to incorporation of the advanced mAbs (Monoclonal Antibodies). Moreover, the demand & adoption of biosimilar monoclonal antibody will further increase by making the way over the growth of market.
According to study, “Global Biosimilar Monoclonal Antibody Market to reach USD 32.05 Billion by 2026” the key companies operating in the global biosimilar monoclonal antibody market are Allergan plc, BIOCAD BioXpress, Therapeutics SA, Biocon Limited, Boehringer Ingelheim GmbH, Celltrion Inc, Coherus BioSciences Inc, Dr. Reddys Laboratories Ltd, Genor BioPharma Co Ltd., Intas Pharmaceuticals Limited.
Based on type, biosimilar monoclonal antibody market is segmented as biopharmaceuticals and synthetic chemicals. Based on product type, market is segmented as Remsima/Inflectra, BI695500, Infimab, FKB238, Reditux, Clotinab, CT-P10, BI695501, BCD-022, FKB327, BCD-021, Mabtas, Maball, AcellBia, Herzuma, Abcixirel and CANMAB/Hertraz. Based on indication, market is segmented as autoimmune diseases, hematology, oncology, gastrointestinal diseases, and others. Based on molecule or drug class, market is segmented as bevacizumab, rituximab, abciximab, trastuzumab, infliximab and adalimumab. In addition, based on distribution channel, market is segmented as hospital pharmacies, specialty pharmacies, retail pharmacies, and others.
The biosimilar monoclonal antibody market is driven by growth in geriatric population, followed by increase in demand for cost effective treatment among patients, and rise in prevalence of diseases, such as rheumatoid arthritis and cancer. However, high cost associated with the manufacturing process of these drugs and severe government regulations towards the absence of pre-analytical tests may impact the market. Moreover, increase in government focus on enhancing health care facilities and growth in collaboration among the Local Players are key opportunities for market.
Based on geography, the North-American region holds major share in global biosimilar monoclonal antibody market owing to presence of advanced healthcare facilities, increase in product approvals, favorable reimbursement scenario and rise in adoption of biosimilar monoclonal antibodies in the region. Whereas, the Asian-Pacific and European regions are projected to witness higher growth rate due to rise in public-private initiative aimed towards boosting advance research practices coupled with increase in investment to promote Biosimilar Monoclonal Antibody research over the forecast period. In upcoming years, it is estimated that future of the global market will be bright caused by increase in focus on research and development (R&D) contributing to innovative product pipeline and growth in health care infrastructure during the forecast period. The global biosimilar monoclonal antibody market is valued approximately at US $27.84 Billion in 2018 and is expected to grow with a healthy growth rate of more than 35.70% over the forecast period 2019 to 2026.
For More Information refer to below link:-
Ankur Gupta, Head Marketing & Communications